Shares of Cellectis S.A. (NASDAQ:CLLS) have been given a consensus recommendation of “Buy” by the eight analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $42.25.

Several research analysts have recently issued reports on the company. BidaskClub cut Cellectis from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research upgraded Cellectis from a “hold” rating to a “buy” rating and set a $32.00 price objective for the company in a research note on Wednesday, July 19th. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of Cellectis in a research note on Saturday, June 3rd. Finally, Jefferies Group LLC restated a “buy” rating and issued a $47.00 price objective on shares of Cellectis in a research note on Wednesday, April 26th.

COPYRIGHT VIOLATION NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2017/08/08/cellectis-s-a-nasdaqclls-given-consensus-recommendation-of-buy-by-brokerages.html.

Shares of Cellectis (NASDAQ CLLS) opened at 23.21 on Tuesday. Cellectis has a 1-year low of $16.09 and a 1-year high of $28.77. The company’s market capitalization is $820.13 million. The firm’s 50 day moving average price is $25.17 and its 200-day moving average price is $23.25.

Hedge funds have recently bought and sold shares of the company. Eqis Capital Management Inc. raised its stake in Cellectis by 27.2% in the second quarter. Eqis Capital Management Inc. now owns 10,687 shares of the biotechnology company’s stock valued at $276,000 after buying an additional 2,287 shares during the period. Sphera Funds Management LTD. bought a new stake in Cellectis during the first quarter valued at approximately $3,832,000. Vident Investment Advisory LLC raised its stake in Cellectis by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 50,994 shares of the biotechnology company’s stock valued at $1,224,000 after buying an additional 8,496 shares during the period. Finally, Trexquant Investment LP bought a new stake in Cellectis during the first quarter valued at approximately $214,000. 16.08% of the stock is currently owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with MarketBeat.com's FREE daily email newsletter.